Highlights:

• Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio®
• Preliminary efficacy data shows a 58% reduction in the rate of disease progression for Cohort 2 (High Dose) using the FDA primary efficacy endpoint, ALSFRS-R
• Confirmation that monepantel and its active metabolite, monepantel...